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To the Editor:
We appreciate the comments of Dr.
Martin-Denavit and co-workers on
our report and the information they
presented, which throws additional
light on the use of serum procalcito-
nin (PCT) for the diagnosis of neona-
tal infection. They regard markedly
increased serum PCT as a marker of
materno-fetal infection, although fe-
tal involvement is difficult to con-
firm. In the absence of microbiologi-
cal evidence, the diagnosis of
infection relies on clinical signs,
which can be found in a variety of
conditions. Alternatively, the high
serum PCT concentrations measured
in eight neonates could represent
maternal PCT, increased by an infec-
tion not involving the fetus, after
passage through the placenta. Given
the low molecular mass ('12 kDa) of
PCT (1 ), transplacental passage of
this substance must be considered,
although we are not aware of any
study dealing with this issue. Parallel
measurements of maternal and neo-
natal serum PCT concentrations at
delivery could give insight into the
possible sources of increased PCT in
the first hours of life.
Regarding the serum PCT concen-
trations in newborn infants without
infection, the data presented by Dr.
Martin-Denavit and co-workers com-
bine with those presented by another
group (2 ) and our group to give a
clearer picture of a physiological
peak in serum PCT occurring be-
tween 12 and 36 h after birth. Physi-
ological peak PCT concentrations
generally are ,20 mg/L; therefore,
values exceeding that limit can be
regarded as a sign of infection even
in this time period.
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Influence of Age and Sex and Day-to-
Day and Within-Day Biological
Variation on Plasma Concentrations
of Fatty Acid-binding Protein and
Myoglobin in Healthy Subjects
To the Editor:
Fatty acid-binding protein (FABP),
like myoglobin (Mb), increases sig-
nificantly within ;3 h after onset of
symptoms of acute myocardial in-
farction (AMI) and returns to health-
related values within 12 to 24 h (1 ).
For the early assessment or exclusion
of AMI, FABP performs better than
Mb (2, 3 ). Although FABP, like Mb,
is also found in skeletal muscle, the
distinct ratio of the contents of Mb
over FABP in heart (ratio, 4–5) and
skeletal muscle (ratio, 20–70) allows
the discrimination between myocar-
dial and skeletal muscle injury (4 ).
For the assessment of clinical ref-
erence values, it is important to
know the possible influence of bio-
logical variations such as age, sex,
and day-to-day and within-day fluc-
tuations (5 ); however, for FABP such
data are lacking. The aim of the
present study was to establish these
parameters for FABP first in a large
group of volunteers of different ages.
Mb was also measured to delineate
possible effects of age and sex on the
ratio of the plasma concentrations of
Mb over FABP. We also studied day-
to-day and within-day biologic vari-
ation (within-person) for both FABP
and Mb concentrations in another
group of volunteers.
For the first substudy, plasma
samples were taken from 312 donors
(110 women and 202 men; ages,
21–70 years) visiting the blood bank
of Lie`ge, Belgium. EDTA was added
to samples to prevent clotting. For
the study of within-person biologic
variation, blood samples were ob-
tained from young and apparently
healthy volunteers (six men and six
women; ages, 19–27 years) recruited
from the student population of
Maastricht University. Samples were
obtained at the following time
points: on day 1, at 0930, 1100, 1400,
1700, 2000, and 2300; on day 2, at
0300, 0700, 0930; and on days 8, 15,
22, 29, and 57 at 0930. Citrate was
added to prevent clotting, and sam-
ples were immediately aliquoted and
frozen at 280 °C until use. The study
was approved by the medical ethics
committee of the Academic Hospital
Maastricht, and all subjects gave in-
formed consent. FABP was mea-
sured with a sensitive noncompeti-
tive sandwich-type ELISA (6 ), using
recombinant human (heart-type)
FABP as the calibrator (7 ). Mb was
measured with a turbidimetric im-
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munoassay (Unimate 3 Myo; Roche
Diagnostic Systems) on a Cobas Mira
plus analyzer (Roche). The inter- and
intraassay analytical imprecision
(CV) was ,10% for FABP (6 ) and
,6% for Mb (Unimate 3 performance
data; Roche). Both assays showed no
interference from either citrate or
EDTA (data not shown). BMDP Sta-
tistical software was used for statis-
tical analysis. All data are presented
as medians, with 25 and 75 percen-
tiles in parentheses. Samples with
values below the detection limit of
0.3 mg/L FABP or 7.5 mg/L Mb were
assigned the detection limit.
The median plasma concentrations
of FABP and Mb in the first substudy
(n 5 312) were 1.5 mg/L (25–75 per-
centiles, 1.1–2.1 mg/L) and 27 mg/L
(25–75 percentiles, 20–36 mg/L), re-
spectively. The median ratio of the
plasma concentrations of Mb over
FABP was 19 (25–75 percentiles, 13–
24). Plasma concentrations of both
cardiac markers showed a sex depen-
dency. Plasma FABP (P ,0.005; Mann–
Whitney test) and Mb (P ,0.0001) val-
ues were lower in women than in men
(Fig. 1). The ratio of Mb over FABP
showed no significant difference be-
tween sexes.
Both cardiac markers also showed
an increase in the health-related
plasma concentration during aging
(Fig. 1). The effect of aging was more
prominent in the plasma concentra-
tion of FABP (P ,0.0001; regression
analysis) than Mb (P ,0.01). As a
result, the ratio of Mb over FABP was
also age-dependent (P ,0.001).
The day-to-day variation in
plasma concentrations of FABP and
Mb, expressed as mean CV (within-
person) of seven time points (days 1,
2, 8, 15, 22, 29, and 57) of all 12
subjects and calculated as CV2
within-person 5 CV2 total 2 CV2
analytical imprecision (5 ) was 14%
for FABP and 18% for Mb. For anal-
ysis of within-day variation of FABP
and Mb, three time blocks were used:
daytime as the most active period
(0930–1700), evening as a more re-
laxed period (1700–0100), and night
as the resting period (0100–0930).
For plasma FABP, a significant in-
crease was seen (P ,0.005; BMDP
Statistical Software, program 2V)
from daytime (0.8 mg/L) to evening
(0.9 mg/L) to night (1.1 mg/L). For
Mb, a similar trend was found from
daytime (20.9 mg/L) to evening (22.6
mg/L) to night (23.1 mg/L); however,
this did not reach statistical signifi-
cance. The overall values for men
[FABP, 1.2 mg/L (0.6–1.6 mg/L); Mb,
25 mg/L (22–29 mg/L)] and women
[FABP, 0.7 mg/L (0.4–1.2 mg/L); Mb,
20 mg/L (15–22 mg/L)] confirm the
data of the first substudy (age group,
21–30 years).
The measured median plasma
FABP (1.5 mg/L) and Mb (27 mg/L)
concentrations of healthy subjects are
similar to previously published val-
ues of 1.6 mg/L for FABP and 33
mg/L for Mb (1, 6 ), as are the differ-
ences in Mb plasma values between
men and women (8, 9 ). The observed
increases of the FABP and Mb
plasma concentrations with age, es-
pecially after 50 years, are most likely
explained by the decrease in renal
function in elderly people, which in
the case of Mb may be partly coun-
terbalanced by diminishing skeletal
muscle mass, especially in men (10 ).
Both cardiac markers show differ-
ences between men and women,
which might be explained by the fact
that men have a relatively larger
muscle mass than women.
The within-day variations found
for FABP may be related to the re-
ported increased glomerular filtra-
tion rate during the day (11 ); how-
ever, this explanation is not
confirmed by a significant within-
day variation of Mb. A limitation of
this substudy is that observations
were made for subjects 19–27 years
of age, whereas most acute coronary
syndromes appear in older persons.
In conclusion, this study shows
that when using FABP and (or) Mb
as plasma markers for the diagnosis
Fig. 1. Median plasma concentrations (25 and75 percentiles) of FABP (A), Mb (B), and the ratio
of Mb over FABP (C) in apparently healthy men ( ) and women (M) of different age groups.
Numbers above bars refer to the number of subjects studied.
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of AMI, the time of day is of minor
relevance; age and sex, however, are
more important because these will
influence the upper reference con-
centrations of both these markers. In
addition, caution should be taken
when using the Mb over FABP ratio
to discriminate cardiac from skeletal
muscle injury, especially for patients
.50 years of age.
We thank N. Drees, Roche Diag-
nostic Systems, for stimulating dis-
cussions and for providing the Mb
assays.
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Influence of Gender in Growth
Hormone Status in Adults: Role of
Urinary Growth Hormone
To the Editor:
A recent paper by Engstrom et al. (1 )
presented marked gender differences
in plasma growth hormone (GH) val-
ues in young adults (21–26 years of
age), evaluated in the consulting
room and after overnight fasting.
The authors observed higher values
in the women than in the men. They
proposed that something in the
morning triggers a GH burst in al-
most all of the women but in very
few of the men.
Veldhuis in the 24th International
Symposium in Antwerp (GH and
Growth Factors in Endocrinology and
Metabolism, October 1997; informa-
tion printed by Sterling Press, UK,
for Pharmacia & Upjohn) affirmed
that gender itself has a major impact
on the secretion of GH in adults.
Unfortunately, until now the basis of
sexual dimorphism in GH secretory
patterns/status in humans has not
fully understood. However, several
works suggest that estrogens play an
important role in GH secretion in
women compared with men. Lang et
al. (2 ) observed a difference in re-
sponse to growth hormone-releasing
hormone (GHRH) in premeno-
pausal, but not postmenopausal,
women compared with men. There-
fore, estrogens seem to increase the
GHRH-stimulated GH secretion.
Main et al. (3 ) revealed a signifi-
cant impact of gender on urinary GH
values. They included children in the
study and collected the first morning
voiding for 3 days per subject.
The urinary GH values, collected
from 70 healthy adults (22–61 years)
drug free, in the ambulatory state-
,and after overnight fasting are re-
ported here. This population was di-
vided twice (by gender and age) into
four groups to investigate a possible
influence of gender in GH status;
these groups were as follows: group
A, men less than 40 years of age
(range, 22–39 years), n 5 18; group B,
women less than 40 years of age
(range, 19–40 years), n 5 25; group
C, men more than 40 years of age
(range, 43–61 years), n 5 17; and
group D, women more than 40 years
of age (range, 41–59 years), n 5 10
(five of the women were postmeno-
pausal).
This study was approved by the
Bioethics Committee of the Medical
School of the University of Padova.
To evaluate GH status, other mark-
ers such as plasma GH and growth
hormone-binding protein (GHBP)
were analyzed. The latter is a circulat-
ing protein, generated from the extra-
cellular domain of the GH receptor
through a proteolytic cleavage.
Statistical analysis was performed
using ANOVA-LSD.
The plasma GH concentration and
urine GH excretion (reported as
ng/L and as ng/g of creatinine) in 70
adults are summarized in Table 1.
Values are expressed as mean 6 SD.
Urinary GH values (expressed both
as ng/L and ng/g of creatinine) were
higher in women than in men in the
younger groups. In groups C and D,
there was no difference between
male and female urinary GH values
(0.98 6 1.50 vs 1.02 6 1.52 ng/L and
1.55 6 2.83 vs 1.90 6 3.19 ng/g of
creatinine, respectively). Further-
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